Ensysce Biosciences (NASDAQ:ENSC) Releases Earnings Results, Beats Expectations By $0.17 EPS

Ensysce Biosciences (NASDAQ:ENSC) announced its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.17, Zacks reports. The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.30 million. Ensysce Biosciences had a negative net margin of 660.96% and a negative return on equity of 598.21%.

Ensysce Biosciences Price Performance

ENSC traded up $0.01 during mid-day trading on Friday, hitting $0.41. The stock had a trading volume of 61,814 shares, compared to its average volume of 668,123. The stock’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.68. The firm has a market capitalization of $3.10 million, a price-to-earnings ratio of -0.11 and a beta of 0.85. Ensysce Biosciences has a 1-year low of $0.36 and a 1-year high of $2.06.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.